1. [CASE 1 — QUESTION 1] A 58-year-old male receives a deceased-donor renal transplant and is started on tacrolimus, mycophenolate mofetil (MMF), and prednisone. Five weeks post-transplant, his creatinine rises from 1.4 to 2.3 mg/dL over 72 hours. He has no fever or graft tenderness. Tacrolimus trough is 15.8 ng/mL against a target of 8–12 ng/mL. Donor-specific antibody (DSA) testing is negative. The intern suggests starting pulse methylprednisolone immediately for presumed acute rejection. Which of the following best explains why empirical treatment without biopsy is inappropriate, and what is the most informative next step?

• A) Empirical treatment is inappropriate because the negative DSA result excludes acute rejection entirely; the rising creatinine with a supratherapeutic trough must represent calcineurin inhibitor (CNI) nephrotoxicity, and biopsy would expose the patient to procedural risk without adding diagnostic information; tacrolimus dose reduction should be initiated immediately without biopsy.
• B) Empirical treatment is inappropriate because both acute calcineurin inhibitor (CNI) nephrotoxicity and acute rejection present with rising creatinine and cannot be reliably distinguished by clinical features alone; CNI toxicity produces biopsy findings of tubular vacuolization and afferent arteriolar hyalinosis without lymphocytic infiltration, while rejection produces tubulitis and interstitial inflammation — biopsy is required to confirm the diagnosis and direct treatment, since augmenting immunosuppression in a patient with CNI toxicity would be harmful without benefit.
• C) Empirical treatment is inappropriate because pulse methylprednisolone is contraindicated in the first six weeks post-transplant; the appropriate empirical treatment for a creatinine rise at this stage is antithymocyte globulin (ATG), which is effective for both CNI toxicity and rejection through its dual mechanism of T-cell depletion and renal vasodilatation.
• D) Empirical treatment is inappropriate because rising creatinine at five weeks post-transplant most likely represents ureteral obstruction from periureteral edema; biopsy is premature and ultrasound to exclude obstruction should precede any pharmacological intervention.
• E) Empirical treatment is inappropriate because the supratherapeutic trough indicates the patient is over-immunosuppressed; pulse corticosteroids in an over-immunosuppressed patient carry unacceptable infection risk; tacrolimus should be held entirely for 48 hours before any further diagnostic workup.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. Allograft biopsy returns showing tubular cell vacuolization, afferent arteriolar hyalinosis, and mild interstitial edema without lymphocytic tubulitis or interstitial inflammation. There is no peritubular capillary C4d deposition. The pathologist reports the findings are consistent with calcineurin inhibitor (CNI) nephrotoxicity. Which of the following is the most appropriate immediate management?

• A) Initiate pulse methylprednisolone 500 mg intravenously daily for three days; the biopsy finding of interstitial edema indicates subclinical T-cell mediated rejection (TCMR) that requires corticosteroid treatment before the lymphocytic infiltration becomes histologically apparent on repeat biopsy.
• B) Initiate antithymocyte globulin (ATG) at 1.5 mg/kg/day for 10 days; afferent arteriolar hyalinosis is a vascular rejection lesion equivalent to Banff grade IIA that mandates T-cell depleting salvage therapy to prevent irreversible endothelial injury.
• C) Initiate plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab; the absence of C4d on this biopsy does not exclude antibody-mediated rejection (AMR) because C4d-negative AMR is recognized in the Banff classification and the arteriolar hyalinosis represents subclinical endothelial antibody injury.
• D) Hold tacrolimus entirely for five days and substitute cyclosporine at standard induction doses; complete transition to an alternative calcineurin inhibitor (CNI) is required when acute nephrotoxicity is confirmed on biopsy, as further exposure to the offending agent at any dose will perpetuate hyalinosis.
• E) Reduce the tacrolimus dose to target a trough within the therapeutic range of 8–12 ng/mL, recheck the trough in 48–72 hours, and monitor creatinine for improvement; acute CNI nephrotoxicity from afferent arteriolar vasoconstriction is dose-related and reversible with dose reduction — augmenting immunosuppression is not indicated and would be harmful.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. Tacrolimus dose was reduced and the trough returned to 7.4 ng/mL with creatinine improving to 1.6 mg/dL. Three weeks later the trough rises again to 19.2 ng/mL without any dose change. A medication reconciliation reveals that the patient was started on fluconazole by his primary care physician for oral candidiasis one week ago. Which mechanism best explains the recurrent trough elevation?

• A) Fluconazole is a potent inhibitor of cytochrome P450 3A4 (CYP3A4) — the principal enzyme responsible for tacrolimus hepatic and intestinal first-pass metabolism — causing a marked reduction in tacrolimus clearance and accumulation of tacrolimus to supratherapeutic concentrations; the tacrolimus dose must be reduced urgently and trough monitoring intensified for the duration of the fluconazole course.
• B) Fluconazole inhibits P-glycoprotein (P-gp) efflux transporter in the renal tubule of the transplanted kidney, reducing tacrolimus urinary excretion and causing systemic tacrolimus accumulation; the interaction is confined to the renal compartment and does not affect hepatic tacrolimus metabolism.
• C) Fluconazole displaces tacrolimus from erythrocyte binding sites, increasing the free (unbound) plasma tacrolimus fraction measured by the trough assay; since immunosuppressive efficacy depends on free rather than total tacrolimus, the elevated trough does not represent excess drug effect and no dose adjustment is required.
• D) Fluconazole directly inhibits the calcineurin enzyme, producing additive calcineurin inhibition beyond what tacrolimus provides at the current dose; the elevated trough reflects not drug accumulation but rather a sensitization of the calcineurin assay to the combined inhibitory effect of both agents.
• E) Fluconazole activates the pregnane X receptor (PXR) in hepatocytes, upregulating CYP3A4 transcription and paradoxically increasing tacrolimus clearance; the apparent trough rise is a laboratory artifact from fluconazole cross-reactivity with the immunoassay used to measure tacrolimus in whole blood.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. The fluconazole interaction was managed and the patient remained stable on tacrolimus for three years. A protocol biopsy at year three shows moderate striped tubulointerstitial fibrosis with tubular atrophy and afferent arteriolar hyalinosis. Tacrolimus troughs have consistently been within the 5–8 ng/mL therapeutic range throughout. Creatinine has slowly increased from 1.4 to 2.0 mg/dL over 18 months. Which of the following correctly identifies this finding and the most appropriate pharmacological management strategy?

• A) The biopsy findings represent chronic active T-cell mediated rejection (TCMR) — striped tubulointerstitial fibrosis with tubular atrophy is the Banff histological signature of chronic TCMR — and the appropriate treatment is pulse methylprednisolone followed by optimization of tacrolimus trough to the higher end of the therapeutic range.
• B) The biopsy findings represent chronic antibody-mediated rejection (AMR) driven by low-level DSAs that have fallen below the detection threshold of standard solid-phase assays; the appropriate treatment is empirical plasmapheresis plus rituximab to reduce the subclinical DSA burden responsible for the progressive tubulointerstitial injury.
• C) The biopsy findings represent polyomavirus BK nephropathy; striped tubulointerstitial fibrosis is the classic pattern of BK virus tubular injury, and the appropriate management is reduction of total immunosuppression burden with serial BK virus plasma polymerase chain reaction (PCR) monitoring.
• D) The biopsy findings represent chronic calcineurin inhibitor (CNI) nephrotoxicity — progressive striped tubulointerstitial fibrosis driven by long-term transforming growth factor beta (TGF-β) stimulation of interstitial fibroblasts — a process that is largely irreversible once established; the appropriate management is CNI minimization, specifically conversion to a reduced-dose CNI combined with an mTOR inhibitor (sirolimus or everolimus) or a CNI-free mTOR inhibitor-based regimen, to slow ongoing TGF-β-driven fibrogenesis.
• E) The biopsy findings represent calcineurin inhibitor (CNI)-induced membranous nephropathy from immune complex deposition; the appropriate treatment is substitution of tacrolimus with mycophenolate mofetil (MMF) alone as the primary immunosuppressive agent, since the calcineurin pathway is responsible for the immune complex deposition driving the membranous pattern.

5. [CASE 2 — QUESTION 1] A 46-year-old female renal transplant recipient has been stable on tacrolimus for two years with consistent troughs of 6–8 ng/mL. She develops fever, new pulmonary nodules on computed tomography (CT), and positive serum galactomannan, consistent with invasive pulmonary aspergillosis. Voriconazole is initiated. Within five days her tacrolimus trough is 24.1 ng/mL and she reports tremor and headache. Which of the following correctly identifies the mechanism of this drug interaction and the appropriate management response?

• A) Voriconazole competes with tacrolimus for binding to FKBP12 in lymphocytes, reducing the effective pharmacodynamic potency of tacrolimus at the calcineurin level and causing a compensatory upregulation of tacrolimus production by lymphocytes that paradoxically raises the measured trough without increasing immunosuppression.
• B) Voriconazole activates the pregnane X receptor (PXR) in hepatocytes, causing a transient upregulation of CYP3A4 that initially increases tacrolimus production in hepatocytes before the induction phase reverses at day seven; the trough will normalize spontaneously without dose adjustment within ten days of voriconazole initiation.
• C) Voriconazole is a potent inhibitor of cytochrome P450 3A4 (CYP3A4), the principal enzyme responsible for tacrolimus hepatic and intestinal metabolism, causing a marked reduction in tacrolimus clearance and accumulation to supratherapeutic concentrations; the tacrolimus dose must be reduced substantially — often by 50–75% — with daily trough monitoring during the voriconazole course to prevent nephrotoxicity and neurotoxicity.
• D) Voriconazole inhibits renal P-glycoprotein (P-gp) in the proximal tubule, impairing urinary tacrolimus excretion and raising systemic tacrolimus exposure; the interaction is isolated to the renal excretion pathway and does not involve hepatic CYP3A4 metabolism, so the dose reduction should be calculated based on the estimated glomerular filtration rate reduction caused by tacrolimus accumulation.
• E) Voriconazole is a calcineurin activator that counteracts tacrolimus-mediated calcineurin inhibition; the elevated trough reflects a compensatory increase in tacrolimus synthesis driven by decreased calcineurin inhibitory activity in the hypothalamus; the dose should be increased further to restore adequate calcineurin inhibition in the presence of voriconazole.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. Voriconazole is completed after a six-week course and the aspergillosis resolves. The tacrolimus dose is retitrated back to baseline. Two months later, she is found to have a positive interferon-gamma release assay for latent tuberculosis and is started on rifampin monotherapy. Within two weeks, her tacrolimus trough falls from 7.1 to 2.3 ng/mL despite no dose change. Which of the following correctly explains this opposite pharmacokinetic effect compared to voriconazole?

• A) Rifampin is a potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) through activation of the pregnane X receptor (PXR) in hepatocytes; upregulation of CYP3A4 dramatically accelerates tacrolimus first-pass metabolism while upregulation of intestinal P-gp increases tacrolimus efflux back into the gut lumen, reducing tacrolimus bioavailability to critically subtherapeutic levels and placing the patient at acute rejection risk — this is the pharmacological opposite of the voriconazole interaction and requires urgent major tacrolimus dose escalation with daily trough monitoring.
• B) Rifampin is a calcineurin activator that reverses tacrolimus-mediated calcineurin inhibition, reducing the effective immunosuppression without changing plasma tacrolimus levels; the measured trough of 2.3 ng/mL represents laboratory cross-reactivity between rifampin and the tacrolimus immunoassay, and the actual tacrolimus exposure is unchanged; no dose adjustment is required.
• C) Rifampin competitively displaces tacrolimus from FKBP12 binding sites in lymphocytes, reducing effective drug-receptor occupancy despite adequate plasma trough levels; the dose should be increased to compensate for FKBP12 displacement, but the relationship between plasma level and immunosuppressive effect is altered for the duration of the rifampin course.
• D) Rifampin inhibits intestinal esterases responsible for tacrolimus conversion from its prodrug form, reducing bioavailability; the appropriate management is to switch from oral to intravenous tacrolimus administration for the duration of the rifampin course to bypass the intestinal esterase blockade.
• E) Rifampin increases renal tubular secretion of tacrolimus through organic anion transporter 1 (OAT1) induction in the transplanted kidney, causing rapid renal elimination of tacrolimus that cannot be corrected by oral dose escalation alone; intravenous tacrolimus is required to maintain therapeutic plasma levels during the rifampin course.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. Despite urgent tacrolimus dose escalation after rifampin initiation, the patient presents one week later with creatinine rising from 1.3 to 2.2 mg/dL. Tacrolimus trough has been maintained at only 3.1 ng/mL despite doses that would normally produce troughs of 8–10 ng/mL without rifampin. Donor-specific antibody testing is negative. Allograft biopsy shows Banff grade IB T-cell mediated rejection with significant tubulitis and moderate interstitial inflammation without vascular involvement. Which of the following is the most appropriate first-line treatment for this rejection episode?

• A) Initiate plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab immediately; the negative DSA result on standard solid-phase assay does not exclude antibody-mediated rejection because non-HLA antibodies — including anti-MICA and anti-AT1R antibodies — can cause Banff grade IB-equivalent tubulitis without conventional DSA positivity.
• B) Increase the tacrolimus dose further until a trough of 15–18 ng/mL is achieved; supratherapeutic trough targeting will provide sufficient calcineurin inhibition to reverse early TCMR without requiring pulse corticosteroids and avoids the risk of corticosteroid-mediated HPA axis suppression in a patient who is already immunologically vulnerable.
• C) Substitute rifampin with isoniazid plus pyrazinamide for latent tuberculosis treatment; the TCMR episode is a direct consequence of rifampin-induced subtherapeutic tacrolimus levels and will resolve spontaneously once the CYP3A4 induction is eliminated and the tacrolimus trough normalizes within five to seven days.
• D) Initiate pulse methylprednisolone 500 mg intravenously daily for three consecutive days as first-line treatment for Banff grade IB T-cell mediated rejection (TCMR); simultaneously, the underlying cause — rifampin-mediated CYP3A4 induction producing subtherapeutic tacrolimus trough — should be addressed by substituting rifampin with an alternative antituberculous regimen that does not induce CYP3A4.
• E) Initiate antithymocyte globulin (ATG) at 1.5 mg/kg/day immediately for 14 days; Banff grade IB TCMR in the context of CYP3A4 induction is classified as steroid-resistant by definition because the inducing drug makes adequate corticosteroid delivery impossible at standard pulse doses, warranting direct escalation to ATG without a steroid trial.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. Pulse methylprednisolone was completed and rifampin was substituted with isoniazid. Seven days after completing pulse steroids, the creatinine remains elevated at 2.1 mg/dL and has not trended toward baseline. Tacrolimus trough is now 7.8 ng/mL following rifampin discontinuation. The transplant team determines that the rejection episode has not responded to first-line corticosteroid treatment. Which of the following correctly identifies this clinical situation and the appropriate next therapeutic step?

• A) This clinical situation represents adequate but delayed steroid response; TCMR with interstitial inflammation requires up to four weeks for creatinine to return to baseline after pulse steroids because the interstitial inflammatory infiltrate resolves slowly; the appropriate next step is to repeat the biopsy at four weeks to confirm resolving inflammation before considering additional treatment.
• B) This clinical situation meets the definition of steroid-resistant T-cell mediated rejection (TCMR) — failure of creatinine to return toward baseline within five to seven days of completing pulse corticosteroid therapy; the appropriate next step is antithymocyte globulin (ATG) at 1.5 mg/kg/day for 10–14 days to deplete the alloreactive T-cell population driving ongoing graft injury.
• C) This clinical situation indicates that the rejection is actually antibody-mediated rather than T-cell mediated despite the biopsy findings; steroid resistance in TCMR is pathognomonic for subclinical AMR, and the appropriate next step is immediate plasmapheresis plus IVIG plus rituximab without repeat biopsy.
• D) This clinical situation indicates that the rifampin-induced CYP3A4 induction has not yet fully reversed; subtherapeutic tacrolimus during the rejection episode has allowed T-cell clonal expansion that cannot be reversed by corticosteroids alone or by ATG; the only effective intervention is plasmapheresis to remove the expanded alloreactive T-cell clones from the circulation.
• E) This clinical situation represents adequate first-line treatment response; serum creatinine is expected to plateau for two to three weeks after pulse steroids before beginning to decline because corticosteroids suppress the inflammatory cytokine milieu driving creatinine elevation without directly reversing tubular cell injury; a second pulse course of 250 mg methylprednisolone for three days should be administered if creatinine has not fallen by week three.

9. [CASE 3 — QUESTION 1] A 63-year-old male who received a renal transplant four years ago is maintained on azathioprine, tacrolimus, and prednisone. He presents to rheumatology with his first gout flare involving the first metatarsophalangeal joint; serum uric acid is 9.8 mg/dL. His rheumatologist initiates allopurinol 300 mg daily without contacting the transplant team. Three weeks later the patient presents to the emergency department with profound fatigue, fever, and oral ulcers. Complete blood count shows white blood cell count 0.8 × 10⁹/L, hemoglobin 6.9 g/dL, and platelets 22 × 10⁹/L. Which of the following best explains the mechanism by which this drug combination produced life-threatening pancytopenia?

• A) Allopurinol inhibits thiopurine methyltransferase (TPMT) directly at the enzyme active site, eliminating the primary inactivation pathway for azathioprine's active metabolites; the resulting thioguanine nucleotide accumulation is equivalent to homozygous TPMT deficiency and would occur in all patients regardless of their native TPMT genotype.
• B) Allopurinol chelates azathioprine in the gastrointestinal tract before absorption, preventing its conversion to 6-mercaptopurine (6-MP) by intestinal thiopurines; the paradoxical result is that unmetabolized azathioprine accumulates in bone marrow progenitors as a direct alkylating agent that is more myelotoxic than the thioguanine nucleotide metabolites.
• C) Allopurinol inhibits purine phosphoribosyltransferase in bone marrow progenitors, blocking the salvage pathway that progenitors depend on for DNA replication; azathioprine's block of de novo purine synthesis simultaneously eliminates the de novo pathway, producing complete purine starvation and myelosuppression through bimodal purine synthesis failure.
• D) Allopurinol competes with azathioprine for renal tubular secretion in the transplanted kidney, increasing azathioprine plasma levels through reduced renal clearance; the interaction is pharmacokinetic rather than metabolic and is therefore correctable by reducing the azathioprine dose proportionally to the reduction in renal tubular secretion capacity.
• E) Allopurinol inhibits xanthine oxidase, one of the principal enzymes responsible for catabolizing azathioprine's active thiopurine metabolites including 6-mercaptopurine (6-MP); with xanthine oxidase blocked, 6-MP is shunted almost exclusively through anabolic pathways to produce massive accumulation of thioguanine nucleotides in bone marrow progenitor cells, causing life-threatening myelosuppression even at standard azathioprine doses.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. Azathioprine is immediately discontinued and allopurinol is held. The patient recovers with supportive care. The transplant team switches the antiproliferative component to mycophenolate mofetil (MMF) and then resumes allopurinol safely. The patient's wife, who is 31 years old and of childbearing potential, asks the transplant nurse whether MMF would be safe if she were to become pregnant in the future. Which of the following correctly describes the reproductive safety profile of MMF that must be communicated to the patient's wife in this context?

• A) MMF is safe in pregnancy at standard immunosuppressive doses because the FDA Risk Evaluation and Mitigation Strategy (REMS) program applies only to female patients who are themselves taking MMF; the wife of a male MMF recipient has no pharmacological exposure to MMF and faces no reproductive risk from her husband's treatment.
• B) MMF carries a reproductive risk for the patient's wife only if she is also a renal transplant recipient requiring immunosuppression; healthy partners of male MMF recipients face no teratogenic exposure because mycophenolic acid (MPA) does not concentrate in seminal fluid at concentrations sufficient to cause embryopathy.
• C) The patient's wife should be counseled that this question is not directly relevant to her husband's MMF use — mycophenolic acid (MPA) teratogenicity occurs through maternal systemic exposure during embryonic organogenesis, not through paternal transmission; however, if she herself were ever prescribed MMF for any reason, she would require two forms of contraception throughout treatment and for six weeks after discontinuation because MMF causes characteristic embryopathy including external ear abnormalities, cleft lip and palate, and cardiac defects.
• D) MMF is safe for female partners of male recipients to conceive naturally; the REMS program requires only that male patients using MMF for transplant indications undergo sperm banking before initiation because MMF causes irreversible azoospermia through IMPDH inhibition in Sertoli cells.
• E) The patient's wife should be informed that MMF is classified as pregnancy category X and is absolutely contraindicated in any woman who may potentially be exposed to a male MMF recipient through sexual contact; the FDA recommends barrier contraception for all female partners of male patients on MMF regardless of whether she herself is taking the drug.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. He is now stable on MMF, tacrolimus, and prednisone and doing well on allopurinol without interaction. Six months later he develops a urinary tract infection and is treated with a seven-day course of amoxicillin-clavulanate. The transplant pharmacist notes that MMF efficacy may be transiently reduced during the antibiotic course and explains the pharmacokinetic reason to the patient. Which of the following correctly explains the mechanism by which the antibiotic reduces MMF pharmacological exposure?

• A) Amoxicillin-clavulanate inhibits CYP3A4 in the intestinal wall, reducing conversion of the MMF prodrug to its active metabolite mycophenolic acid (MPA); the reduced prodrug activation decreases peak MPA plasma concentrations and total drug exposure during the antibiotic course.
• B) Amoxicillin-clavulanate eliminates intestinal flora responsible for deconjugating MPA glucuronide (MPAG) back to free mycophenolic acid (MPA) during enterohepatic recirculation; without bacterial deconjugation, the secondary MPA plasma peak that occurs at 6–12 hours after dosing is abolished, reducing total MPA area under the curve and transiently lowering antiproliferative immunosuppressive efficacy.
• C) Amoxicillin-clavulanate competes with mycophenolic acid (MPA) for binding to albumin plasma protein, increasing the free MPA fraction and accelerating MPA renal clearance; the net effect is a shorter MPA half-life and reduced total systemic exposure despite unchanged oral MMF dosing.
• D) Amoxicillin-clavulanate induces hepatic UDP-glucuronosyltransferase (UGT) enzymes, accelerating MPA glucuronidation and increasing the rate of MPA conversion to its inactive MPAG form; accelerated inactivation reduces the steady-state plasma MPA concentration and the duration of therapeutic IMPDH inhibition in lymphocytes.
• E) Amoxicillin-clavulanate inhibits the intestinal transporter OATP1B1 (organic anion transporting polypeptide 1B1), preventing biliary MPAG from re-entering enterocytes for deconjugation; the MPAG that cannot re-enter the enterocytes is excreted in feces, eliminating the enterohepatic recirculation cycle and reducing systemic MPA exposure.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. During a quality improvement review of his near-fatal myelosuppression event, the transplant pharmacist notes that the patient was never tested for thiopurine methyltransferase (TPMT) status before azathioprine was initiated four years ago. She explains that TPMT testing should be performed before azathioprine initiation in all transplant recipients. Why is pre-initiation TPMT testing clinically important for azathioprine, and what would the finding of homozygous TPMT loss-of-function variants have changed about his initial management?

• A) Pre-initiation TPMT testing is clinically important because TPMT is the principal enzyme responsible for inactivating 6-mercaptopurine (6-MP) — the active azathioprine intermediate — through S-methylation; patients with homozygous TPMT loss-of-function variants have absent TPMT activity and cannot inactivate thioguanine nucleotides through this pathway, causing accumulation to life-threatening levels even at standard azathioprine doses; identification of homozygous TPMT deficiency before initiation would have indicated substitution of azathioprine with mycophenolate mofetil (MMF) entirely, avoiding the initial myelosuppression risk independent of the subsequent allopurinol interaction.
• B) Pre-initiation TPMT testing is clinically important because TPMT genotype determines azathioprine bioavailability from the gastrointestinal tract; patients with homozygous TPMT loss-of-function variants absorb ten times more azathioprine from the gut than TPMT-normal patients, and the dose should be reduced by 90% based on the genotype finding before initiation to account for the absorption difference.
• C) Pre-initiation TPMT testing is clinically important because TPMT genotype predicts which patients will develop the allopurinol-azathioprine interaction; only patients with homozygous TPMT loss-of-function variants are susceptible to xanthine oxidase inhibitor co-administration myelosuppression, while TPMT-normal patients can safely receive allopurinol with standard azathioprine doses without the interaction.
• D) Pre-initiation TPMT testing is clinically important because TPMT deficiency causes azathioprine to be metabolized exclusively through CYP3A4 rather than the thiopurine pathway; identifying TPMT deficiency before initiation would have indicated switching from tacrolimus to cyclosporine because tacrolimus's CYP3A4 competition with the diverted azathioprine metabolic pathway produces a pharmacokinetic interaction not seen with cyclosporine.
• E) Pre-initiation TPMT testing is clinically important because TPMT genotype determines allopurinol clearance; patients with homozygous TPMT loss-of-function variants cannot inactivate allopurinol through S-methylation and accumulate oxypurinol to nephrotoxic concentrations in the transplanted kidney; identifying deficiency before initiation would have indicated that allopurinol is contraindicated in this patient independent of the azathioprine interaction.

13. [CASE 4 — QUESTION 1] A 51-year-old female receives her second renal transplant after her first graft failed from chronic rejection seven years ago. Her panel reactive antibody (PRA) is 62% and donor-specific antibodies (DSAs) are detected. The transplant team selects antithymocyte globulin (ATG) for induction at 1.5 mg/kg/day. Before the first ATG infusion is administered, a nursing student asks the charge nurse why premedication is required and what medications constitute the standard premedication regimen. Which of the following correctly describes the standard ATG premedication regimen and the mechanism of the adverse effect it prevents?

• A) Premedication consists of subcutaneous epinephrine 0.3 mg administered fifteen minutes before infusion to prevent IgE-mediated Type I anaphylaxis to the rabbit proteins in ATG; antihistamines and corticosteroids are added only if the patient has a documented prior reaction to ATG or known rabbit protein sensitivity.
• B) Premedication consists of intravenous fluconazole to prevent Candida species superinfection triggered by ATG-mediated T-cell depletion; ATG infusion reactions are not a concern for premedication because they represent expected pharmacodynamic activity, not an adverse drug reaction requiring prevention.
• C) Premedication consists of intravenous furosemide to prevent volume overload from the fluid used to dilute ATG for infusion; the large volume required for ATG administration commonly causes acute pulmonary edema in transplant recipients whose graft function has not yet been established, and diuretic premedication is the standard preventive measure.
• D) Premedication must include a corticosteroid (methylprednisolone), acetaminophen, and an antihistamine administered approximately 30–60 minutes before each ATG infusion; this regimen attenuates the cytokine release syndrome that occurs when polyclonal ATG antibodies bind and lyse large numbers of T cells through complement-mediated and Fc-receptor-mediated cytotoxicity, releasing pro-inflammatory mediators including tumor necrosis factor alpha and interleukin-6 that cause fever, rigors, and hypotension.
• E) Premedication consists of intravenous rituximab administered the day before each ATG infusion to deplete circulating B cells that would otherwise mount an accelerated anti-rabbit IgG antibody response to ATG; without rituximab premedication, anti-ATG antibodies formed after the first dose neutralize subsequent ATG doses within 24 hours.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Despite premedication on post-operative day two, during the third ATG infusion the patient develops fever to 38.9°C, rigors, and blood pressure dropping to 84/50 mmHg. The nurse stops the infusion. A medical student rotating on the service suggests administering intramuscular epinephrine because the patient appears to be having an anaphylactic reaction. The transplant fellow disagrees. Which of the following best explains the fellow's reasoning and the appropriate management of this reaction?

• A) The fellow agrees that this is anaphylaxis but notes that intravenous rather than intramuscular epinephrine is required for a transplant recipient with marginal hemodynamics; the appropriate dose is 0.1 mg intravenous epinephrine over five minutes followed by an epinephrine infusion at 0.05–0.5 mcg/kg/minute.
• B) The fellow correctly identifies this as cytokine release syndrome rather than IgE-mediated anaphylaxis — the mechanism is massive pro-inflammatory cytokine liberation from complement-mediated T-cell lysis rather than mast cell degranulation, and the clinical features of fever, rigors, and hypotension are expected pharmacodynamic consequences of ATG's mechanism; appropriate management is to hold the infusion, administer IV fluids for hemodynamic support, give additional methylprednisolone and antihistamine if not already at maximum premedication doses, and resume the infusion at a slower rate once the patient stabilizes.
• C) The fellow agrees this is anaphylaxis but notes that the current premedication with methylprednisolone should be increased to 1 g IV immediately and the ATG course permanently discontinued because a second anaphylactic episode would be fatal; basiliximab should be substituted to complete the induction course.
• D) The fellow notes that this reaction represents acute serum sickness from immune complex formation between ATG rabbit proteins and the patient's pre-formed anti-rabbit antibodies from prior ATG use seven years ago; the appropriate management is antihistamine and non-steroidal anti-inflammatory drug (NSAID) therapy for seven to fourteen days, and the ATG course should be discontinued and eculizumab initiated as terminal complement inhibition to prevent further immune complex deposition.
• E) The fellow notes that this is a vasovagal reaction triggered by pain from the infusion site; the appropriate management is IV atropine 0.5 mg for the bradycardia component, repositioning the patient supine, and resuming the ATG infusion at a faster rate to minimize total infusion time and reduce future vasovagal risk.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. The ATG course was completed successfully. Six weeks post-transplant, routine surveillance testing detects cytomegalovirus (CMV) viremia with a plasma CMV polymerase chain reaction (PCR) of 4,200 IU/mL. She has no symptoms. The transplant fellow explains to a medical student that this CMV reactivation is mechanistically linked to the ATG induction she received. Which of the following best explains the mechanistic connection between ATG exposure and increased CMV reactivation risk?

• A) ATG contains anti-CMV antibodies derived from immunized rabbits that cross-react with human CMV glycoproteins on the surface of latently infected monocytes; this cross-reactivity paradoxically activates latent CMV by stimulating the monocyte surface receptors that regulate CMV reactivation, making ATG a direct viral activator as well as an immunosuppressant.
• B) ATG selectively depletes natural killer (NK) cells — the primary cellular defense against CMV-infected cells — through the anti-CD56 antibodies present in the polyclonal preparation; T-cell reconstitution is complete within two to three weeks of ATG completion, but NK cell recovery takes six to eight months, leaving a specific NK-cell surveillance gap during which CMV reactivation goes unchecked.
• C) ATG causes profound reduction in serum immunoglobulin levels by depleting plasma cell precursors that express T-cell surface antigens; the resulting secondary hypogammaglobulinemia eliminates neutralizing anti-CMV antibody titers and allows CMV to replicate freely in the absence of humoral immune containment.
• D) ATG increases tacrolimus trough levels through competitive FKBP12 displacement, creating a period of excess calcineurin inhibition in CD8+ cytotoxic T lymphocytes that impairs perforin and granzyme B synthesis; the temporary inability to produce cytotoxic granules rather than absolute lymphopenia is the mechanism that allows CMV to replicate during the post-ATG surveillance gap.
• E) ATG causes profound and sustained lymphopenia by depleting circulating T cells — including the CD8+ cytotoxic T lymphocytes that provide essential surveillance for CMV-infected cells through perforin and granzyme-mediated cytotoxicity; the resulting T-cell surveillance gap allows latent CMV to reactivate without normal immune containment, mandating universal antiviral prophylaxis with valganciclovir or ganciclovir for several months after ATG exposure.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. The CMV viremia is treated with valganciclovir and resolves. The transplant team is preparing a protocol document on ATG use. A pharmacist asks the attending what laboratory parameter is used to guide ATG dosing decisions during an induction or rejection treatment course, and what the target value is during active ATG treatment. Which of the following correctly identifies the monitoring parameter and its therapeutic target during ATG administration?

• A) Serum creatinine is the primary monitoring parameter guiding ATG dosing; the target is a creatinine level below 1.5 mg/dL during ATG treatment, as creatinine elevation above this threshold indicates inadequate T-cell depletion allowing ongoing rejection to persist and mandates dose escalation until renal function stabilizes.
• B) Serum tacrolimus trough is the primary monitoring parameter; ATG dose is adjusted to maintain the tacrolimus trough below 5 ng/mL during the depletion course because ATG-mediated T-cell lysis releases intracellular calcineurin that competes with tacrolimus for FKBP12 binding, requiring reduced tacrolimus exposure during the period of maximum T-cell lysis.
• C) Lymphocyte count — either total lymphocyte count targeting below 0.05 × 10⁹/L or CD3+ T-cell count targeting below 25 cells/mm³ — is the primary monitoring parameter guiding ATG dose and discontinuation decisions; achieving and maintaining target lymphocyte depletion confirms adequate T-cell elimination, while lymphocyte counts above target indicate the need for continued dosing.
• D) Serum complement C3 and C4 levels are the primary monitoring parameters; ATG-mediated complement consumption reduces C3 and C4 as T cells are lysed, and target values of C3 below 0.5 g/L and C4 below 0.1 g/L during treatment confirm that complement-dependent T-cell depletion is occurring at the required rate for adequate immunosuppression.
• E) Absolute neutrophil count (ANC) is the primary monitoring parameter during ATG treatment; the target is an ANC below 500 cells/mm³ because neutropenia at this level indicates adequate bone marrow suppression confirming that ATG has achieved the intended pan-hematopoietic effect required for complete alloimmune reset in high-risk recipients.

17. [CASE 5 — QUESTION 1] A 49-year-old male presents 14 months post-transplant with creatinine rising from 1.2 to 2.4 mg/dL over three weeks. He had a prior failed transplant and his panel reactive antibody (PRA) was 48% at the time of the current transplant. Donor-specific antibody (DSA) testing shows strongly positive anti-HLA class II antibodies. Allograft biopsy demonstrates peritubular capillary C4d deposition, peritubular capillaritis, and glomerulitis without significant tubulitis. Which of the following correctly identifies the rejection type and the diagnostic basis for this classification?

• A) This is antibody-mediated rejection (AMR), diagnosed by the Banff classification triad of microvascular injury (peritubular capillaritis and glomerulitis), peritubular capillary C4d deposition reflecting complement activation by donor-specific antibodies (DSAs) bound to graft endothelium, and positive DSA testing — all three components are present, confirming AMR and distinguishing it from T-cell mediated rejection (TCMR), which requires tubulitis and interstitial inflammation without DSA.
• B) This is T-cell mediated rejection (TCMR) grade IB, because the dominant biopsy finding is peritubular capillaritis, which represents mononuclear cell infiltration of peritubular capillaries driven by alloreactive T cells; DSA positivity is coincidental and does not change the Banff classification when tubulitis score is zero and arteritis score is zero.
• C) This is calcineurin inhibitor (CNI) nephrotoxicity rather than rejection, because peritubular capillary C4d deposition is a consequence of supratherapeutic tacrolimus levels activating complement through the alternative pathway in peritubular capillary endothelium; the DSA is a bystander antibody that predates the transplant and has no pathological role in the current creatinine elevation.
• D) This is mixed rejection with simultaneous TCMR and AMR components; the presence of glomerulitis indicates that T cells are infiltrating glomerular capillaries in a pattern equivalent to Banff vascular TCMR, and the C4d and DSA indicate concurrent AMR; treatment requires simultaneous pulse steroids for the TCMR component and plasmapheresis for the AMR component administered on alternating days.
• E) This is chronic allograft nephropathy rather than acute rejection; the three-week creatinine rise at 14 months post-transplant represents the expected progression of non-immunological graft injury from ischemia-reperfusion, and the C4d deposition and DSA are epiphenomena of the chronic low-grade inflammation that accompanies progressive fibrosis in all long-term allografts.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. The AMR diagnosis is confirmed and the transplant team initiates treatment. A resident asks the attending to explain the rationale for each component of the AMR treatment regimen and why the combination is required rather than any single agent alone. Which of the following correctly describes the three-component AMR treatment regimen and the distinct pharmacological purpose of each component?

• A) The three-component regimen consists of pulse methylprednisolone to suppress T-cell-mediated endothelial injury, antithymocyte globulin (ATG) to deplete the alloreactive T-cell population producing T-cell help for antibody production, and intravenous immunoglobulin (IVIG) to provide anti-idiotype antibodies that neutralize the circulating donor-specific antibodies; plasmapheresis is not part of the standard AMR regimen because it cannot distinguish between donor-specific antibodies and therapeutic immunoglobulins.
• B) The three-component regimen consists of plasmapheresis to remove complement components C3 and C5 from plasma before they are activated by donor-specific antibodies, eculizumab to inhibit terminal complement at the C5 level as a bridge until plasmapheresis reduces overall complement load, and rituximab to deplete NK cells that amplify complement-mediated endothelial injury through antibody-dependent cellular cytotoxicity.
• C) The three-component regimen consists of rituximab to deplete circulating DSAs through its anti-immunoglobulin Fc region binding activity, intravenous immunoglobulin (IVIG) to competitively block DSA binding to donor endothelial HLA antigens, and tacrolimus dose escalation to supratherapeutic levels to provide calcineurin-dependent suppression of the plasma cell differentiation driving ongoing DSA production.
• D) The three-component regimen consists of plasmapheresis to physically remove circulating donor-specific antibodies from plasma, intravenous immunoglobulin (IVIG) administered after each plasmapheresis session to provide replacement immunoglobulins, modulate B-cell and antibody effector mechanisms, and reduce rebound DSA production, and rituximab (anti-CD20 monoclonal antibody) to deplete CD20-positive B cells and memory B cells and suppress ongoing and de novo DSA production — each component addresses a distinct aspect of the antibody-mediated pathophysiology that the others cannot.
• E) The three-component regimen consists of plasmapheresis to remove circulating DSAs, high-dose corticosteroids to suppress the T-cell help driving B-cell antibody class switching, and basiliximab re-induction to block IL-2-driven expansion of the alloreactive T-cell population that is providing cognate help to DSA-producing B cells; rituximab is reserved for AMR refractory to this standard first-line regimen.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. The resident asks why antithymocyte globulin (ATG) — which is more potent overall immunosuppression than any individual component of the AMR regimen — was not used instead of plasmapheresis, IVIG, and rituximab. Which of the following best explains why ATG cannot substitute for the AMR treatment regimen in this patient?

• A) ATG cannot be used for AMR because it is contraindicated in patients with positive donor-specific antibodies; ATG's polyclonal anti-thymocyte antibodies bind to the Fc regions of circulating DSAs and activate complement at the level of the DSA-HLA immune complex in the graft, causing catastrophic complement-mediated graft destruction when administered in the presence of high-titer DSAs.
• B) ATG cannot be used for AMR because the patient already received ATG as induction therapy at the time of transplant and the development of AMR indicates that she is now ATG-refractory; repeat ATG courses produce diminishing T-cell depletion due to immune resistance, making the regimen ineffective for rejection occurring after prior ATG exposure.
• C) ATG achieves its immunosuppressive effect by depleting circulating T cells through complement-mediated and Fc-receptor-mediated lysis of T-cell surface antigen-bearing lymphocytes; ATG is generated against thymocytes and contains antibodies against T-cell surface antigens, not against B cells or plasma cells, and it has no mechanism to remove circulating donor-specific antibodies from plasma or suppress the B cells and plasma cells producing those antibodies — the primary effectors of microvascular endothelial injury in AMR.
• D) ATG cannot be used for AMR because it activates the nuclear factor kappa B (NF-κB) pathway in renal tubular endothelial cells through its Fc-region interaction with tubular Fc-gamma receptors, amplifying the complement-mediated endothelial injury already caused by donor-specific antibodies and worsening graft function rather than protecting it.
• E) ATG cannot be used for AMR because its T-cell depleting mechanism eliminates the regulatory T cells (Tregs) that normally suppress plasma cell DSA production; Treg depletion by ATG paradoxically amplifies antibody production and increases DSA titers, making AMR worse rather than treating it.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. The AMR treatment regimen of plasmapheresis, IVIG, and rituximab is initiated. The attending asks the fellow: what specific laboratory parameter most directly reflects whether the plasmapheresis component of the regimen is achieving its intended pharmacological goal, and what would indicate treatment response versus treatment failure?

• A) Serum tacrolimus trough is the primary monitoring parameter for AMR treatment response; rising tacrolimus trough during plasmapheresis indicates that calcineurin inhibitory activity is being restored as the anti-tacrolimus antibodies produced during rejection are being removed from circulation along with the donor-specific antibodies.
• B) Serum complement C4 level is the primary monitoring parameter; complement C4 is consumed when donor-specific antibodies activate complement on graft endothelium, and rising C4 during plasmapheresis indicates that the donor-specific antibody burden is decreasing and complement activation is abating; a C4 level returning to normal range indicates complete DSA removal.
• C) CD19+ B-cell count is the primary monitoring parameter for AMR treatment response; since rituximab depletes CD20-positive B cells, rising CD19 counts indicate that rituximab has failed to deplete B cells and the dose should be repeated; falling CD19 counts indicate effective B-cell depletion and predict eventual DSA reduction over six to twelve weeks.
• D) Absolute lymphocyte count is the primary monitoring parameter for AMR treatment response; since plasmapheresis and IVIG both reduce circulating lymphocyte counts through their combined immunomodulatory effects, a target absolute lymphocyte count below 0.1 × 10⁹/L during treatment confirms adequate combined immunosuppression and predicts DSA clearance.
• E) Donor-specific antibody (DSA) levels — measured as mean fluorescence intensity (MFI) or antibody titer by solid-phase assay — are the primary monitoring parameter most directly reflecting the pharmacological goal of plasmapheresis, which is physical removal of circulating DSAs; a declining DSA MFI or titer across serial sessions indicates effective removal and treatment response, while persistently elevated or rebounding DSA levels despite multiple sessions indicate treatment failure and the need to reassess the regimen.

21. [CASE 6 — QUESTION 1] A 53-year-old male renal transplant recipient has early biopsy evidence of calcineurin inhibitor (CNI) nephrotoxicity at four weeks post-transplant. The nephrologist converts him from tacrolimus to sirolimus at week five. Two weeks after conversion, the patient presents with separation of the lower transplant wound incision — a 3 cm segment has dehisced — and imaging shows a small perinephric fluid collection. Which of the following correctly identifies the mechanism by which sirolimus caused this surgical complication?

• A) Sirolimus causes wound dehiscence by inhibiting platelet mTORC1, impairing thromboxane A2 synthesis in activated platelets and preventing the platelet plug formation required for early wound hemostasis; the perinephric fluid collection represents continued capillary bleeding into the perinephric space that cannot be contained without the platelet activation required for normal clot retraction.
• B) Sirolimus inhibits mTOR complex 1 (mTORC1) signaling, which is required for the proliferation and migration of fibroblasts that synthesize the collagen matrix of healing wounds and endothelial cells that form the new capillary network essential for tissue oxygenation and repair; mTOR inhibition initiated at week five — before surgical wound healing was complete — impaired both the proliferative and angiogenic phases of wound repair, producing dehiscence and anastomotic breakdown consistent with the perinephric collection.
• C) Sirolimus causes wound dehiscence by inhibiting mTORC2 — the rapamycin-insensitive mTOR complex — in wound macrophages; mTORC2 controls actin cytoskeleton remodeling required for macrophage migration across the wound bed during the inflammatory debridement phase, and mTORC2 inhibition by sirolimus arrests wound macrophage function before fibroblasts can access a clean wound bed.
• D) Sirolimus causes wound dehiscence by inducing hyperlipidemia severe enough to impair microvascular perfusion at the wound margins; triglyceride-laden microvessels in the subcutaneous tissue surrounding the incision develop mechanical obstruction from lipid aggregation, producing ischemic wound margin necrosis that results in suture line failure.
• E) Sirolimus causes wound dehiscence through its direct antiproliferative effect on keratinocytes at the skin surface; mTORC1 inhibition prevents keratinocyte migration across the wound gap during re-epithelialization, leaving the underlying fascial and subcutaneous layers mechanically intact but without epidermal coverage, causing superficial wound separation without deep tissue or anastomotic involvement.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. Sirolimus was discontinued after the wound complication, and the patient was restarted on low-dose tacrolimus. The wound healed fully over eight weeks. Three months later, the transplant team re-initiates sirolimus as a CNI-minimization strategy, this time waiting until six months post-transplant when wound healing is confirmed. After four months on sirolimus, the patient develops progressive exertional dyspnea, dry cough, and bilateral ground-glass opacities on chest computed tomography (CT). Bronchoalveolar lavage (BAL) cultures are negative for all pathogens. Which of the following is the most likely diagnosis and appropriate management?

• A) The most likely diagnosis is Pneumocystis jirovecii pneumonia (PCP) with a false-negative bronchoalveolar lavage; sirolimus mTORC1 inhibition impairs CD4+ T-cell proliferative responses to Pneumocystis, which reduces the alveolar inflammatory response that normally produces detectable BAL organisms; empirical trimethoprim-sulfamethoxazole at PCP treatment doses should be initiated immediately.
• B) The most likely diagnosis is sirolimus-induced hyperlipidemia causing lipoid pneumonitis; VLDL-laden alveolar macrophages (lipophages) accumulate in the alveolar spaces as a consequence of mTORC1-mediated impairment of macrophage lipid catabolism; sirolimus should be dose-reduced to the lower end of the therapeutic range and high-intensity statin therapy initiated before considering drug discontinuation.
• C) The most likely diagnosis is tacrolimus-associated pulmonary edema from excess calcineurin inhibition in pulmonary vascular endothelium causing increased microvascular permeability; the low-dose tacrolimus co-administered with sirolimus is the causative agent; sirolimus should be continued and tacrolimus discontinued, with the sirolimus dose adjusted upward to compensate for reduced calcineurin inhibitory coverage.
• D) The most likely diagnosis is acute antibody-mediated rejection (AMR) presenting as pulmonary-renal syndrome with concurrent allograft DSA production causing complement-mediated injury to pulmonary capillary endothelium; DSA testing should be performed urgently and if positive, plasmapheresis plus rituximab initiated without waiting for a confirmatory biopsy.
• E) The most likely diagnosis is sirolimus-associated non-infectious pneumonitis — a recognized class effect of mTOR inhibitors caused by mTORC1 inhibition in pulmonary interstitial cells that produces bilateral ground-glass opacities with a comprehensively negative infectious workup; sirolimus must be discontinued, with most cases resolving over weeks after drug cessation, and an alternative CNI-sparing or CNI-minimization strategy must be considered given this patient's prior CNI nephrotoxicity.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. Sirolimus was discontinued and the pneumonitis resolved. The patient was maintained on tacrolimus monotherapy supplemented by MMF. At year four post-transplant, a protocol biopsy shows moderate striped tubulointerstitial fibrosis with tubular atrophy and afferent arteriolar hyalinosis. Tacrolimus troughs have been consistently therapeutic at 5–7 ng/mL. Creatinine has slowly risen from 1.3 to 1.9 mg/dL over 24 months. What is the correct diagnosis, and what does this finding tell the clinician about the nature and reversibility of the underlying injury?

• A) The biopsy demonstrates chronic active T-cell mediated rejection (TCMR) — the progressive tubulointerstitial fibrosis with tubular atrophy is the classic Banff pattern of chronic allograft injury from ongoing low-level alloreactive T-cell inflammation; treatment with pulse methylprednisolone followed by tacrolimus target trough increase to 10–12 ng/mL will reverse the fibrotic process over the following 12 months.
• B) The biopsy demonstrates recurrent IgA nephropathy in the allograft — IgA nephropathy is the most common cause of renal failure leading to transplantation, and recurrence rates of 50–80% at five years produce progressive tubulointerstitial fibrosis through mesangial IgA-mediated complement activation; treatment requires high-dose fish oil supplementation and tacrolimus dose escalation.
• C) The biopsy demonstrates BK polyomavirus nephropathy — the tubular atrophy and interstitial fibrosis are classic BK virus cytopathic injury patterns, and the diagnosis requires BK virus plasma PCR and renal biopsy immunostaining for SV40 large T antigen to confirm; treatment is immunosuppression reduction to restore BK-specific cellular immunity.
• D) The biopsy demonstrates chronic calcineurin inhibitor (CNI) nephrotoxicity — progressive striped tubulointerstitial fibrosis driven by long-term transforming growth factor beta (TGF-β) stimulation of interstitial fibroblasts — a pathological process that is largely irreversible once established; reducing the tacrolimus dose will slow further fibrogenesis but cannot restore fibrotic tissue, and given this patient's prior adverse reactions to both sirolimus (wound healing impairment and pneumonitis), the CNI-minimization strategy must be individualized — either accepting the lowest tolerable CNI dose with close monitoring, or evaluating alternative CNI-sparing approaches such as belatacept.
• E) The biopsy demonstrates calcineurin inhibitor (CNI)-mediated membranoproliferative glomerulonephritis from calcineurin-dependent complement pathway dysregulation; the appropriate treatment is conversion from tacrolimus to mycophenolate mofetil (MMF) as the sole immunosuppressive agent because calcineurin inhibition drives the complement dysregulation and removal of calcineurin blockade will restore normal complement regulation.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. The transplant team agrees that the year-four biopsy confirms chronic CNI nephrotoxicity and that CNI minimization is needed to slow further fibrogenesis, but notes that this patient's history of sirolimus-related wound dehiscence and pneumonitis makes mTOR inhibitor re-challenge high-risk. Which of the following best describes a pharmacologically rational CNI-minimization strategy for this patient that avoids mTOR inhibitor exposure?

• A) The most pharmacologically rational strategy is to reduce tacrolimus to the lowest dose maintaining adequate immunosuppression — targeting the lower end of the therapeutic trough range — while optimizing MMF dosing to provide maximum antiproliferative coverage at the reduced CNI level; this reduces ongoing TGF-β-driven fibrogenesis without exposing the patient to mTOR inhibitor-associated risks; alternatively, belatacept — a CTLA4-Ig fusion protein that blocks CD28-B7 costimulation and prevents T-cell activation by a calcineurin-independent mechanism — may be considered as a CNI-sparing strategy in patients with CNI nephrotoxicity and mTOR inhibitor intolerance.
• B) The most pharmacologically rational strategy is to discontinue tacrolimus entirely and substitute azathioprine as the sole immunosuppressive agent because azathioprine's thiopurine incorporation into lymphocyte DNA provides T-cell suppression equivalent to calcineurin inhibition; tacrolimus-free azathioprine monotherapy avoids all CNI toxicity and does not require TPMT genotyping in patients already on stable azathioprine.
• C) The most pharmacologically rational strategy is to add high-dose prednisone (40 mg daily) to the existing regimen; glucocorticoids suppress TGF-β transcription through NF-κB inhibition and will reverse established interstitial fibrosis over 12–18 months of treatment; the dose is then tapered to maintenance once the fibrosis has resolved on repeat biopsy.
• D) The most pharmacologically rational strategy is to immediately discontinue all immunosuppression and place the patient on the waiting list for a second transplant; established striped interstitial fibrosis indicates that graft survival beyond two years is unlikely, and continued immunosuppression exposes the patient to toxicity without benefit at this stage of allograft injury.
• E) The most pharmacologically rational strategy is to convert from tacrolimus to cyclosporine because cyclosporine does not stimulate TGF-β signaling in renal tubular cells; while cyclosporine is a calcineurin inhibitor like tacrolimus, its cyclophilin-binding mechanism produces calcineurin inhibition through a pathway that is TGF-β-independent at the renal tubular level, making it safe to use in patients with documented tacrolimus-induced TGF-β fibrosis without risk of accelerating the fibrotic process.

25. [CASE 7 — QUESTION 1] A 44-year-old female renal transplant recipient with no prior history of diabetes or glucose intolerance receives a transplant and is maintained on tacrolimus 7 mg daily, MMF, and prednisone 10 mg daily. At week eight post-transplant, her fasting glucose is 174 mg/dL on three consecutive measurements, confirming post-transplant diabetes mellitus (PTDM). Her hemoglobin A1c before transplant was 5.4%. The endocrinologist asks the transplant team to explain the pharmacological mechanism of PTDM in this patient and whether both immunosuppressive agents are contributing. Which of the following best explains the dual diabetogenic contribution of her current regimen?

• A) Both tacrolimus and prednisone cause PTDM through the same mechanism — glucocorticoid receptor-mediated suppression of insulin gene transcription in pancreatic beta cells; tacrolimus acts as a partial agonist at the glucocorticoid receptor at supratherapeutic trough levels, and prednisone acts as a full agonist; the two agents summate at the same receptor to produce additive beta-cell insulin gene suppression.
• B) Tacrolimus causes PTDM by inducing autoimmune beta-cell destruction through a mechanism equivalent to Type 1 diabetes — calcineurin inhibition in regulatory T cells eliminates the Treg-mediated suppression of autoreactive anti-islet T cells, allowing existing autoreactive clones to destroy beta cells in the transplant recipient who was previously in prediabetic homeostasis; prednisone exacerbates this process by suppressing the counter-regulatory cortisol response.
• C) Tacrolimus inhibits the calcineurin-NFAT signaling pathway in pancreatic beta cells — a pathway required for glucose-stimulated insulin secretion — reducing the beta cell's secretory response to rising plasma glucose; prednisone independently produces peripheral insulin resistance through glucocorticoid receptor-mediated impairment of insulin signal transduction in skeletal muscle and adipose tissue; the two mechanisms are pharmacologically independent and additive, explaining why the combination is substantially more diabetogenic than either agent alone.
• D) Tacrolimus causes PTDM by activating mTOR complex 1 (mTORC1) in pancreatic alpha cells, stimulating glucagon secretion and raising hepatic glucose output; prednisone independently activates the same mTORC1 pathway in adipocytes, driving lipolysis and releasing free fatty acids that impair insulin signaling; both mechanisms converge on excess hepatic glucose production rather than impaired beta-cell insulin secretion.
• E) Both tacrolimus and prednisone cause PTDM through peripheral mechanisms only — neither agent affects pancreatic beta-cell insulin secretory capacity; tacrolimus impairs GLUT4 vesicle translocation to skeletal muscle cell membranes through calcineurin-dependent cytoskeletal changes, while prednisone reduces insulin receptor expression in adipocytes; both impair glucose uptake rather than insulin production.

26. [CASE 7 — QUESTION 2] Continuing with the same patient. PTDM is managed with insulin. At 18 months post-transplant, a dual-energy X-ray absorptiometry (DEXA) scan shows lumbar spine T-score of −2.1 and femoral neck T-score of −1.9, consistent with osteoporosis and osteopenia respectively. The patient is not on calcium or vitamin D supplementation. The endocrinologist explains to a medical student that corticosteroid-induced bone loss results from multiple converging mechanisms rather than a single pathway. Which of the following best describes the multi-mechanism pathophysiology of corticosteroid-induced osteoporosis and the corresponding preventive interventions that should have been in place from the time of transplantation?

• A) Corticosteroid-induced osteoporosis results from at least four converging mechanisms: direct glucocorticoid receptor-mediated suppression of osteoblast differentiation and function reducing bone formation; upregulation of RANKL expression increasing osteoclast activity and bone resorption; reduced intestinal calcium absorption through impaired vitamin D-dependent calcium transporter expression; and reduced renal calcium reabsorption increasing urinary calcium losses; all transplant recipients on maintenance corticosteroids should have received calcium and vitamin D supplementation from the time of transplant initiation, with baseline and serial DEXA monitoring to detect progressive bone loss requiring pharmacological intervention with bisphosphonates.
• B) Corticosteroid-induced osteoporosis results exclusively from osteocyte apoptosis — the most mechanistically dominant pathway — through direct glucocorticoid receptor-mediated activation of caspase-3 in osteocytes; osteoblast and osteoclast effects are secondary consequences of osteocyte loss; the preventive intervention is weight-bearing exercise to provide the mechanical stimulation that compensates for impaired osteocyte mechanosensing.
• C) Corticosteroid-induced osteoporosis results from gonadal hormone suppression — the HPA axis suppression from chronic prednisone reduces FSH and LH secretion, eliminating estrogen and testosterone that provide the primary trophic support for bone remodeling; the preventive intervention is hormone replacement therapy rather than calcium and vitamin D supplementation, which does not address the underlying gonadal hormone deficit.
• D) Corticosteroid-induced osteoporosis in transplant recipients results primarily from tacrolimus-mediated inhibition of calcineurin in osteoclasts, which paradoxically activates osteoclast function through calcineurin-NFAT pathway disruption; corticosteroids are additive but not the primary cause; the preventive intervention is switching from tacrolimus to cyclosporine, which has lower osteoclast calcineurin inhibitory activity.
• E) Corticosteroid-induced osteoporosis results from NF-κB suppression in bone marrow stromal cells, which prevents the pro-inflammatory cytokine production required to drive osteoblast precursor differentiation; corticosteroids paradoxically eliminate the inflammatory signaling that bone remodeling requires; the preventive intervention is bisphosphonate therapy initiated simultaneously with corticosteroid treatment regardless of baseline DEXA score.

27. [CASE 7 — QUESTION 3] Continuing with the same patient. Bisphosphonate therapy and calcium and vitamin D supplementation are initiated. Two years later — now three and a half years post-transplant — the patient presents with a five-month history of progressive right hip pain that began insidiously and worsens with weight-bearing and stair climbing. She denies fever, joint swelling, or erythema. Plain radiograph of the right hip is reported as normal. The transplant physician suspects a specific corticosteroid-related complication of high-dose induction methylprednisolone exposure three and a half years ago. Which of the following correctly identifies the diagnosis, the appropriate confirmatory imaging, and the multi-mechanism pathophysiology linking high-dose corticosteroid exposure to this condition?

• A) The suspected diagnosis is corticosteroid-induced proximal myopathy of the hip girdle musculature — glucocorticoids cause type IIb muscle fiber atrophy through glucocorticoid receptor-mediated myosin heavy chain degradation in type IIb fibers; electromyography (EMG) with nerve conduction studies is the appropriate confirmatory test; X-ray is normal because the pathology is muscular rather than osseous.
• B) The suspected diagnosis is avascular necrosis (osteonecrosis) of the femoral head; high-dose corticosteroids disrupt the vascular supply to subchondral bone through fat cell hypertrophy increasing intraosseous pressure and compressing terminal vascular channels, intravascular fat embolism occluding terminal arteries supplying the femoral head, and direct glucocorticoid-mediated osteocyte apoptosis; plain radiograph is insensitive for early disease and is frequently normal for months after symptom onset; magnetic resonance imaging (MRI) is the gold standard for early diagnosis, detecting characteristic subchondral signal changes before radiographic collapse.
• C) The suspected diagnosis is septic arthritis of the hip from Candida species; transplant recipients on long-term immunosuppression are susceptible to indolent fungal joint infections that progress over months without the acute features of bacterial septic arthritis; ultrasound-guided joint aspiration with fungal culture is the confirmatory test and the normal X-ray reflects absence of bony destruction at this early stage of infection.
• D) The suspected diagnosis is gout of the hip joint; tacrolimus reduces renal uric acid excretion and long-term low-dose prednisone causes renal urate retention; the combination produces progressive hyperuricemia with eventual deposition of monosodium urate crystals in the hip bursa; synovial fluid aspiration with polarized light microscopy for needle-shaped negatively birefringent crystals is the confirmatory test.
• E) The suspected diagnosis is stress fracture of the femoral neck from bisphosphonate-associated atypical subtrochanteric fracture; bisphosphonates suppress bone remodeling through osteoclast apoptosis, allowing microfracture accumulation in the subtrochanteric femoral region; MRI shows a transverse fracture line with periosteal thickening — the pathognomonic pattern of bisphosphonate-associated atypical femoral fracture.

28. [CASE 7 — QUESTION 4] Continuing with the same patient. MRI confirms avascular necrosis of the right femoral head with subchondral collapse, requiring total hip replacement. She is maintained on prednisone 7.5 mg daily and has been on corticosteroids continuously for three and a half years. The anesthesiology team asks whether stress-dose corticosteroids are required perioperatively. Which of the following correctly explains the physiological rationale for perioperative stress-dose corticosteroid administration in this patient and what would occur without it?

• A) Stress-dose corticosteroids are required because total hip replacement generates an acute inflammatory response that activates T cells capable of triggering allograft rejection while the patient's attention is focused on the orthopedic procedure; the stress dose provides additional graft-protective immunosuppression above the maintenance prednisone level during the perioperative surgical inflammatory window.
• B) Stress-dose corticosteroids are required because propofol and volatile anesthetic agents competitively inhibit glucocorticoid receptor binding in the hypothalamus, transiently eliminating the residual suppressive effect of maintenance prednisone on the HPA axis and creating a transient window of cortisol deficiency during the procedure that requires exogenous supplementation.
• C) Stress-dose corticosteroids are not required because the patient is already receiving 7.5 mg prednisone daily — equivalent to approximately 30 mg hydrocortisone — which exceeds the physiological daily cortisol production of 20–25 mg hydrocortisone and provides sufficient glucocorticoid coverage for major surgical stress without additional supplementation.
• D) Chronic administration of 7.5 mg prednisone daily for three and a half years suppresses the hypothalamic-pituitary-adrenal (HPA) axis through sustained negative feedback, causing adrenal cortical atrophy and eliminating the adrenal gland's ability to mount an endogenous cortisol surge; under major surgical stress, a physiologically intact HPA axis would produce approximately 75–150 mg hydrocortisone equivalent per day — far exceeding what 7.5 mg prednisone provides — and without perioperative stress-dose corticosteroids the patient risks adrenal crisis with refractory hypotension, hyponatremia, and cardiovascular collapse.
• E) Stress-dose corticosteroids are required because total hip replacement procedures involve bone cement (polymethylmethacrylate) that inhibits CYP3A4 in the systemic circulation after absorption from the prosthetic interface, dramatically reducing prednisone conversion to its active form prednisolone and causing relative glucocorticoid deficiency throughout the perioperative period.